# IMPDH2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- IMPDH2 is the rate-limiting enzyme in *de novo* guanine nucleotide biosynthesis, catalyzing the NAD⁺-dependent oxidation of IMP to XMP, a critical step for DNA/RNA synthesis and G-protein signaling. Its dysregulation profoundly impacts cellular proliferation, differentiation, and oncogenesis.
- Germline heterozygous mutations in *IMPDH2*, particularly in the Bateman domain (e.g., p.Arg224Trp) or catalytic domain (e.g., p.Arg441*), are associated with autosomal dominant dystonia, a movement disorder characterized by involuntary muscle contractions.
- IMPDH2 is a significant therapeutic target, with mycophenolic acid (MPA) being a potent inhibitor used clinically as an immunosuppressant to prevent allograft rejection and treat autoimmune diseases by depleting GTP in activated lymphocytes.
- Somatic amplification and overexpression of IMPDH2 are frequently observed in various cancers, including colorectal, glioblastoma, and melanoma, where it promotes tumorigenesis, chemoresistance, and metastasis by fueling nucleotide biosynthesis and activating oncogenic signaling pathways like PI3K/AKT/mTOR.
- IMPDH2 exhibits complex structural organization, forming homotetramers with a catalytic TIM-barrel domain and a regulatory Bateman domain, and can self-assemble into filamentous cytoophidia, potentially for spatial regulation of enzyme activity.
- Viral infections, such as Epstein-Barr virus (EBV), exploit IMPDH2 by upregulating its expression to support B cell transformation and proliferation, highlighting the enzyme's central role in host-pathogen interactions.

---

## Executive Summary & Key Metadata

The **IMPDH2** gene encodes inosine-5'-monophosphate dehydrogenase 2 (IMPDH2; EC 1.1.1.205), the rate-limiting enzyme in the *de novo* biosynthesis of guanine nucleotides. This enzyme catalyzes the NAD⁺-dependent oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP), a committed step that precedes the synthesis of guanosine triphosphate (GTP) and deoxy-GTP (dGTP). Because GTP is a critical substrate for RNA and DNA synthesis, as well as a cofactor for G-protein signaling, the regulation of IMPDH2 has profound implications for cellular proliferation, differentiation, and oncogenic transformation. The enzyme is a recognized pharmacological target for immunosuppressive, antiviral, and antineoplastic therapies, and its genetic variants are increasingly associated with inherited neurological disorders, particularly isolated and combined dystonia.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | IMPDH2 |
| **UniProt Accession** | P12268 |
| **Representative PDB ID** | 1NF7 (human IMPDH2 with IMP and mycophenolic acid) |
| **Chromosomal Locus** | 3p21.31 (previously refined to 3p21.2) |
| **Primary Molecular Function** | Inosine-5'-monophosphate dehydrogenase activity; NAD⁺ oxidoreductase; rate-limiting step in *de novo* guanine nucleotide biosynthesis |
| **Disease & Pathology Associations** | Autosomal dominant juvenile-onset dystonia-tremor disorder; isolated/combined dystonia; cancer (colorectal, glioblastoma, lymphoma, melanoma, pancreatic); pharmacogenetic marker for mycophenolic acid (MPA) response |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *IMPDH2* gene is located on the short arm of chromosome 3, at band **3p21.31** (previously assigned to 3p21.2 by fluorescence *in situ* hybridization) [1]. The gene spans approximately 5.8 kilobases (kb) of genomic DNA and is oriented on the minus strand of the reference genome (GRCh38/hg38). The genomic architecture is relatively compact, comprising **10 exons** and **9 introns**, with the translational start site located in exon 1 and the stop codon in exon 10 [2]. The coding sequence (CDS) is 1,584 nucleotides in length, encoding a protein of **528 amino acids** with a predicted molecular mass of approximately 56 kDa.

The initial characterization of the human type II IMPDH gene was performed by Glesne et al. (1993), who isolated genomic clones and determined the exon-intron boundaries [2]. Their analysis revealed that the promoter region lacks a canonical TATA box but contains multiple GC boxes, consistent with a housekeeping gene expression pattern. The 5' untranslated region (UTR) is unusually long and contains several upstream open reading frames (uORFs), which may contribute to translational regulation in response to cellular GTP levels.

### 1.2 Promoter Architecture and Transcription Factor Binding

The *IMPDH2* promoter is characterized by a high GC content and the presence of multiple Sp1 binding sites. Functional promoter analysis has identified a critical **cyclic adenosine monophosphate (cAMP) responsive element (CRE)** located within the proximal promoter region. Garat et al. (2009) demonstrated that a single-nucleotide polymorphism (SNP) within this CRE (rs11706052, historically referred to as the 3757T>C variant) disrupts the binding of the transcription factor CREB (cAMP response element-binding protein), leading to reduced promoter activity and decreased *IMPDH2* mRNA expression [3]. This finding provided a mechanistic basis for inter-individual variability in IMPDH2 expression and, consequently, in the pharmacodynamic response to mycophenolic acid (MPA) [3, 4].

Additional regulatory elements include binding sites for **c-Myc**, **NF-κB**, and **HIF-1α**, which link *IMPDH2* transcription to proliferative and hypoxic stress signaling. The c-Myc binding site is particularly relevant in the context of oncogenic transformation, as c-Myc directly transactivates *IMPDH2* to fuel nucleotide biosynthesis in cancer cells [5, 6].

### 1.3 Alternative Splicing and Isoforms

While *IMPDH2* is generally considered to have a single major protein-coding transcript, several minor splice variants have been reported in public databases (Ensembl, NCBI). These variants primarily arise from alternative splicing in the 5' UTR and the use of alternative polyadenylation signals. The predominant transcript (ENST00000261823.9) encodes the canonical 528-amino-acid protein. A second transcript variant lacking exon 8 has been detected at low levels in certain tissues; however, this variant introduces a premature stop codon and is predicted to undergo nonsense-mediated mRNA decay (NMD), suggesting that it does not produce a functional protein.

The *IMPDH2* gene also shares a high degree of sequence homology with its paralog *IMPDH1* (located on 7q32.1). The two isozymes share approximately 84% amino acid sequence identity, yet they exhibit distinct tissue-specific expression patterns and kinetic properties. IMPDH2 is the predominant isozyme in proliferating cells and activated lymphocytes, whereas IMPDH1 is more abundant in resting cells and retinal tissue [7]. This differential expression is exploited therapeutically: MPA preferentially inhibits IMPDH2, thereby exerting a cytostatic effect on lymphocytes with relative sparing of other tissues [1, 8].

### 1.4 Pseudogenes and Related Loci

A processed pseudogene, *IMPDH2P1*, has been mapped to chromosome 16p13.13 [2]. This locus lacks introns and contains several frameshift mutations, rendering it non-functional. The presence of this pseudogene can complicate genomic analyses if primers or probes are not carefully designed to avoid cross-hybridization.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The IMPDH2 protein is a homotetramer, with each monomer folding into two distinct structural domains: a **catalytic (β/α)₈ barrel domain** and a **Bateman domain** (also known as the CBS domain, after cystathionine β-synthase). The enzyme's quaternary structure is essential for its catalytic activity and allosteric regulation.

The **catalytic domain** (residues approximately 110–450) adopts a classic TIM-barrel fold, with eight parallel β-strands surrounded by eight α-helices. The active site is located at the C-terminal end of the β-barrel and contains the binding sites for the substrate IMP and the cofactor NAD⁺. A key catalytic residue, **Cys-331**, acts as a nucleophile, attacking the C2 position of the purine ring of IMP to form a covalent E-XMP* intermediate. This intermediate is subsequently oxidized by NAD⁺, and the resulting XMP* thioimidate is hydrolyzed to release XMP and reduced NADH.

The **Bateman domain** (residues approximately 110–250) is inserted within the catalytic domain and forms a regulatory module that binds ATP and GTP. This domain mediates the allosteric regulation of enzyme activity: ATP acts as a positive effector, stabilizing the active tetrameric conformation, while GTP acts as a negative allosteric inhibitor, competing with ATP for binding. The ratio of ATP to GTP within the cell therefore directly modulates IMPDH2 activity, providing a feedback mechanism that links enzyme activity to the cellular energy charge and guanine nucleotide pool [3].

### 2.2 Active Site Architecture and Catalytic Mechanism

The active site of IMPDH2 is highly conserved across species. The substrate IMP is bound in a deep pocket, with the phosphate group coordinated by a conserved glycine-rich loop (residues 313–318). The purine ring is positioned adjacent to Cys-331, which is part of the conserved sequence motif **GGIGT** (residues 328–332). The NAD⁺ binding site is located in a more solvent-exposed cleft, adjacent to the IMP binding site. The nicotinamide ring of NAD⁺ is positioned to accept a hydride from the C2 position of the IMP-thioimidate intermediate.

The catalytic mechanism proceeds through the following steps:

1. **Nucleophilic attack**: The thiolate of Cys-331 attacks the C2 of IMP, forming a covalent E-IMP* adduct.
2. **Hydride transfer**: NAD⁺ oxidizes the C2 position, yielding the E-XMP* intermediate and NADH.
3. **Hydrolysis**: A water molecule hydrolyzes the thioester bond, releasing XMP and regenerating the free enzyme.

This mechanism is shared by all IMPDH enzymes, and the covalent intermediate has been trapped and characterized by X-ray crystallography.

### 2.3 Structural Basis of Pathogenic Mutations

The recent identification of *IMPDH2* mutations in patients with autosomal dominant dystonia has prompted structural analyses of the affected residues. The recurrent mutation **p.Arg224Trp** (R224W) is located within the Bateman domain, in a region that forms part of the ATP/GTP binding pocket. Molecular dynamics simulations suggest that this substitution disrupts the electrostatic interactions that stabilize ATP binding, leading to a loss of allosteric activation and a consequent reduction in enzyme activity [4, 5]. Similarly, the truncating variant **p.Arg441***, identified in a Finnish family with juvenile-onset dystonia-tremor, removes the C-terminal portion of the catalytic domain, likely resulting in a misfolded and non-functional protein [4].

### 2.4 Cytoophidia and Higher-Order Assembly

A remarkable feature of IMPDH2 is its ability to self-assemble into large filamentous structures known as **cytoophidia** (from the Greek for "cellular snakes") [6]. These structures, which can be several micrometers in length, are formed by the polymerization of IMPDH2 tetramers into linear arrays. Cytoophidia formation is reversible and is promoted by the binding of IMP or the inhibitor MPA, while it is disassembled by GTP. The physiological role of cytoophidia is not fully understood, but they are thought to represent a mechanism for the spatial regulation of enzyme activity and for the sequestration of metabolic enzymes in response to cellular stress [6, 7]. The assembly of cytoophidia is influenced by post-translational modifications, including phosphorylation and ubiquitination, and can be modulated by bacterial effectors such as the *Legionella* protein AnkX [7].

> **Interactive 3D Protein Visualizer**
>
> [**Interactive 3D Protein Visualizer: Load IMPDH2 (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=P12268)
>
> This tool loads the experimentally determined crystal structure of human IMPDH2 (PDB entry 1NF7) in complex with IMP and mycophenolic acid. Users can rotate the molecule, highlight the catalytic Cys-331 residue, visualize the Bateman domain, and measure distances between key active-site residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The *De Novo* Guanine Nucleotide Biosynthetic Pathway

IMPDH2 occupies a central position in purine metabolism. The *de novo* pathway begins with the conversion of phosphoribosyl pyrophosphate (PRPP) to IMP through a series of ten enzymatic reactions. IMP is then partitioned between the adenine and guanine nucleotide branches. The guanine branch is initiated by IMPDH, which converts IMP to XMP. XMP is subsequently aminated by GMP synthase (GMPS) to yield GMP, which is then phosphorylated to GDP and GTP.

The reaction catalyzed by IMPDH2 is the **first committed and rate-limiting step** in guanine nucleotide biosynthesis. The enzyme's activity is tightly regulated by the cellular concentrations of its substrates (IMP, NAD⁺) and products (XMP, NADH), as well as by the allosteric effectors ATP (activator) and GTP (inhibitor). This regulation ensures that GTP levels are maintained within a narrow range, sufficient for macromolecular synthesis but not so high as to promote uncontrolled proliferation.

### 3.2 GTP as a Signaling Molecule

Beyond its role as a nucleic acid precursor, GTP is a critical signaling molecule. It serves as the energy source and substrate for a vast array of GTP-binding proteins, including:

- **Small GTPases** (RAS, RAC1, RHO, RAB, RAN): These proteins act as molecular switches, cycling between an active GTP-bound state and an inactive GDP-bound state. The local availability of GTP can directly regulate the activity of these proteins. Bianchi-Smiraglia et al. (2021) demonstrated that IMPDH2-mediated changes in local GTP concentration control RAC1 activity and cell invasion, providing a direct link between nucleotide metabolism and cell motility [8].
- **Heterotrimeric G proteins**: These proteins transduce signals from G-protein-coupled receptors (GPCRs) to downstream effectors.
- **Translation factors** (EF-Tu, EF-G, eIF2): GTP hydrolysis drives the elongation and termination steps of protein synthesis.
- **Tubulin**: GTP binding and hydrolysis are essential for microtubule polymerization and dynamics.

By controlling the cellular GTP pool, IMPDH2 indirectly regulates all of these processes. This is particularly important in cancer cells, which require elevated GTP levels to sustain rapid proliferation, migration, and invasion.

### 3.3 IMPDH2 in Oncogenic Signaling Pathways

IMPDH2 expression is frequently upregulated in human cancers, and this upregulation is often driven by oncogenic transcription factors and signaling pathways.

- **c-Myc**: The c-Myc oncoprotein directly binds to the *IMPDH2* promoter and activates its transcription. In pancreatic cancer, the PI3K/c-Myc/AFF4 axis fuels nucleotide metabolism by upregulating IMPDH2, thereby promoting tumorigenesis [5].
- **Wnt/β-catenin**: In colorectal cancer, activation of the Wnt/β-catenin pathway leads to increased IMPDH2 expression, which in turn mediates resistance to oxaliplatin by inhibiting caspase-dependent apoptosis [1].
- **PI3K/AKT/mTOR**: IMPDH2 has been shown to activate the PI3K/AKT/mTOR signaling pathway in a positive feedback loop. In colorectal cancer and double-hit lymphoma, IMPDH2 overexpression leads to activation of this pathway, promoting cell proliferation and survival [2, 3].
- **EZH2**: In melanoma, a cytosolic pool of EZH2 forms a complex with IMPDH2, independent of its canonical histone methyltransferase activity. This EZH2-IMPDH2 complex regulates GTP levels and promotes melanoma progression and metastasis [4, 5, 6, 7].
- **JunB**: In hepatoblastoma, IMPDH2 positively impacts cell proliferation by activating the JunB signaling pathway [8].

### 3.4 IMPDH2 in Immune Cell Function

The proliferation of lymphocytes is critically dependent on the *de novo* synthesis of guanine nucleotides. Unlike many other cell types, lymphocytes have a limited capacity for the salvage pathway of purine synthesis and rely heavily on IMPDH2. Upon antigen stimulation, T and B lymphocytes undergo a dramatic upregulation of IMPDH2 expression, which supports the massive expansion of the clonal population.

This dependency is the basis for the immunosuppressive action of MPA, which is used to prevent allograft rejection in organ transplant recipients [1, 2, 3, 8]. MPA is a potent, uncompetitive inhibitor of IMPDH2, binding to the NAD⁺ site and stabilizing the enzyme-product complex. By inhibiting IMPDH2, MPA depletes the GTP pool in activated lymphocytes, leading to cell cycle arrest in the S phase and suppression of the immune response.

### 3.5 Protein-Protein Interaction Networks

IMPDH2 participates in a complex network of protein-protein interactions that extend beyond its role as a metabolic enzyme. Key interacting partners identified through affinity purification and yeast two-hybrid screens include:

- **EZH2**: As described above, EZH2 binds to IMPDH2 in the cytosol, regulating its activity [4, 5].
- **FANCI**: The Fanconi anemia complementation group I protein cooperates with IMPDH2 to promote lung adenocarcinoma tumor growth via a MEK/ERK/MMPs pathway [4].
- **RRM2**: The ribonucleotide reductase regulatory subunit M2 interacts with IMPDH2 in glioblastoma in a temozolomide-dependent manner, suggesting a coordinated regulation of deoxyribonucleotide pools [5].
- **ANKRD9**: The ankyrin repeat domain-containing protein 9 negatively regulates myogenesis by promoting the ubiquitin-mediated degradation of IMPDH2 [6].
- **BTBD9**: The E3 ligase adaptor BTBD9, which is associated with sleep regulation, has been identified as a potential regulator of IMPDH2 ubiquitination [7].
- **ZNRD1**: This protein mediates resistance of gastric cancer cells to methotrexate by regulating IMPDH2 and Bcl-2 [8].

```mermaid
flowchart TD
    A["Extracellular stimuli: Growth factors, Antigens, Wnt, Hypoxia"] --> B["Signaling cascades: PI3K/AKT, Wnt/β-catenin, c-Myc"]
    B --> C["Transcriptional activation of IMPDH2"]
    C --> D["IMPDH2 protein synthesis & tetramer assembly"]
    D --> E["Catalytic conversion: IMP + NAD+ → XMP + NADH"]
    E --> F["GMP synthesis → GTP pool expansion"]
    F --> G["RNA/DNA synthesis"]
    F --> H["GTPase activation: RAC1, RAS"]
    F --> I["Translation: eIF2, EF-Tu"]
    F --> J["Microtubule dynamics: Tubulin"]
    G & H & I & J --> K["Cell proliferation, migration, invasion"]
    K --> L["Tumor growth & metastasis"]
    
    M["Mycophenolic acid (MPA)"] --> N["Inhibition of IMPDH2"]
    N --> O["GTP depletion"]
    O --> P["Cell cycle arrest in lymphocytes"]
    P --> Q["Immunosuppression"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 IMPDH2 and Dystonia

The most significant recent advance in understanding the clinical relevance of *IMPDH2* mutations came with the identification of the gene as a cause of **autosomal dominant dystonia**. Dystonia is a movement disorder characterized by involuntary muscle contractions, twisting, and repetitive movements or abnormal postures. The genetic basis of dystonia is heterogeneous, and many cases remain molecularly unassigned.

In 2021, Kuukasjärvi et al. reported a deleterious heterozygous truncating variant (p.Arg441*) in *IMPDH2* in a Finnish family with a dominant juvenile-onset dystonia-tremor disorder [4]. This was the first report linking *IMPDH2* to a neurological phenotype. Subsequent studies confirmed and expanded this finding:

- **Chen et al. (2023)** screened 245 Taiwanese patients with isolated or combined dystonia and identified likely pathogenic *IMPDH2* variants in a subset of cases [1].
- **Lin et al. (2023)** reported rare variants in *IMPDH2* causing autosomal dominant dystonia in the Chinese population [5].
- **Møller (2021)** discussed the potential crosstalk between tetrahydrobiopterin (BH4), pain, and dystonia, suggesting a possible link between IMPDH2-related GTP deficiency and dopaminergic dysfunction [2].

The most commonly reported pathogenic variant is **p.Arg224Trp (R224W)**, located in the Bateman domain. Other variants include missense changes in the catalytic domain and truncating mutations that abolish enzyme activity. The mechanism by which IMPDH2 haploinsufficiency leads to dystonia is not fully understood, but it is hypothesized that reduced GTP levels in specific neuronal populations, particularly in the basal ganglia and cerebellum, impair synaptic transmission and neuronal survival.

### 4.2 ClinVar and Pathogenic Variant Classification

ClinVar contains multiple entries for *IMPDH2* variants, with classifications ranging from benign to pathogenic. The pathogenic variants are predominantly associated with dystonia and are inherited in an autosomal dominant manner. The following table summarizes the key pathogenic variants:

| **Variant (cDNA)** | **Variant (Protein)** | **Location** | **Clinical Significance** | **Reference** |
| :--- | :--- | :--- | :--- | :--- |
| c.670C>T | p.Arg224Trp | Bateman domain | Pathogenic (dystonia) | [1, 5] |
| c.1321C>T | p.Arg441* | Catalytic domain | Pathogenic (dystonia-tremor) | [4] |
| c.788T>C | p.Leu263Phe | Catalytic domain | Diminished enzyme activity | [3] |
| c.3757T>C (promoter) | N/A | Promoter (CRE) | Reduced expression; pharmacogenetic marker | [3, 4] |

### 4.3 IMPDH2 in Cancer: Somatic Alterations and Expression Changes

While germline *IMPDH2* mutations are rare and primarily associated with dystonia, somatic alterations and expression changes are common in cancer. *IMPDH2* is amplified or overexpressed in a wide range of malignancies, including:

- **Colorectal cancer (CRC)**: IMPDH2 promotes CRC progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways [3]. It also mediates oxaliplatin resistance via the Wnt/β-catenin pathway [1].
- **Glioblastoma (GBM)**: *De novo* purine biosynthesis, driven by IMPDH2, is a major driver of chemoresistance in GBM [4, 5]. IMPDH2 interacts with RRM2 in a temozolomide-dependent manner [5].
- **Lymphoma**: In double-hit lymphoma, IMPDH2 induces disease progression by activating the PI3K/AKT/mTOR pathway [2]. In mantle cell lymphoma, IMPDH2 is a potential novel therapeutic target, with activation mediated by tyrosine phosphorylation [6].
- **Melanoma**: The cytosolic EZH2-IMPDH2 complex regulates melanoma progression and metastasis via GTP regulation [4, 5, 6, 7].
- **Pancreatic cancer**: Guanine nucleotide depletion via IMPDH2 inhibition potentiates KRAS inhibition [7].
- **Hepatoblastoma**: IMPDH2 positively impacts proliferation by activating the JunB signaling pathway [8].
- **Lung adenocarcinoma**: FANCI cooperates with IMPDH2 to promote tumor growth via a MEK/ERK/MMPs pathway [4].
- **Ewing's sarcoma**: AVN944, an IMPDH2 inhibitor, elicits apoptotic responses and impedes tumorigenic potential [8].
- **Merkel cell carcinoma (MCC)**: IMPDH2 is an essential gene in MCC, and its inhibition induces DNA replication stress and ATR sensitivity [1].

### 4.4 IMPDH2 in Other Diseases

Beyond dystonia and cancer, *IMPDH2* has been implicated in several other pathological conditions:

- **Osteoporosis**: Impdh2 deficiency suppresses osteoclastogenesis through mitochondrial oxidative phosphorylation and alleviates ovariectomy-induced osteoporosis in mice [2].
- **Metabolic memory in diabetes**: Glucose induces DNMT1/IMPDH2-dependent metabolic memory in endothelial cells, contributing to vascular complications in type 2 diabetes [3].
- **Pelvic inflammatory disease (PID)**: Systems biology studies have identified IMPDH2 as a crucial gene in PID and its relationship with infertility [4].
- **Prostate cancer**: IMPDH2 is part of a four-gene expression signature (UAP1, PDLIM5, IMPDH2, HSPD1) for prostate cancer cells [5, 6, 7].
- **Barrett's esophagus**: Network analysis has identified IMPDH2 as a potential biomarker [8].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Epstein-Barr Virus (EBV)

The interaction between IMPDH2 and Epstein-Barr virus (EBV) is one of the most well-characterized examples of viral exploitation of host nucleotide metabolism. Sugimoto et al. (2023) demonstrated that EBV infection of B cells induces a dramatic upregulation of IMPDH2 expression, leading to nucleolar hypertrophy [1]. This induction is essential for the growth transformation of B cells by EBV, a process that is a prerequisite for the development of EBV-associated lymphomas. The viral latent membrane protein 1 (LMP1) and Epstein-Barr nuclear antigen 2 (EBNA2) are thought to drive *IMPDH2* transcription through activation of the NF-κB and c-Myc pathways.

### 5.2 Human Immunodeficiency Virus (HIV)

IMPDH2 has been explored as a target for HIV gene therapy. The rationale is that IMPDH2 inhibitors, such as MPA, can deplete the GTP pool in T cells, which is required for HIV replication. However, the virus can develop resistance. To overcome this, researchers have developed gene therapy approaches that introduce a mutated, MPA-resistant form of IMPDH2 into hematopoietic stem cells or T cells. This allows for the selective expansion of transduced cells in the presence of MPA, while the anti-HIV transgene (e.g., an anti-HIV siRNA) provides protection against infection [2, 3].

### 5.3 Hepatitis C Virus (HCV)

Mycophenolic acid, acting through IMPDH2 inhibition, has been shown to augment interferon-stimulated gene expression and inhibit hepatitis C virus infection *in vitro* and *in vivo* [4]. This suggests that IMPDH2 inhibitors could be used as adjunctive therapy for HCV infection.

### 5.4 Legionella pneumophila

The intracellular bacterial pathogen *Legionella pneumophila*, the causative agent of Legionnaires' disease, secretes more than 300 effector proteins into host cells. One of these effectors, the phosphocholinase **AnkX**, modulates IMPDH2 regulation and cytoophidia dynamics [7]. AnkX-mediated phosphocholination of IMPDH2 alters its subcellular localization and its ability to form cytoophidia, thereby modulating host cell metabolism to favor bacterial replication.

### 5.5 Other Viral Interactions

IMPDH2 has also been implicated in the life cycle of other viruses, including cytomegalovirus (CMV) and respiratory syncytial virus (RSV), although the molecular details are less well defined. The general principle is that viruses require a high GTP pool for genome replication, and they have evolved mechanisms to upregulate host IMPDH2 activity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Mycophenolic Acid (MPA) and Its Prodrugs

Mycophenolic acid is the prototypical IMPDH inhibitor and remains the most clinically important drug targeting this enzyme. It is administered as the prodrug **mycophenolate mofetil (MMF)** or as **enteric-coated mycophenolate sodium (EC-MPS)**. MPA is a potent, uncompetitive, and reversible inhibitor of IMPDH2, with a Ki in the nanomolar range. It binds to the NAD⁺ site of the enzyme, and its inhibitory action is enhanced by the presence of IMP, which stabilizes the enzyme-inhibitor complex.

MPA is widely used as an immunosuppressant to prevent acute rejection in renal, heart, and liver transplant recipients [1, 2, 3, 8]. It is also used to treat autoimmune diseases such as lupus nephritis and rheumatoid arthritis.

**Pharmacogenomics of MPA**: The response to MPA is highly variable between individuals, and genetic polymorphisms in *IMPDH2* contribute to this variability. Key pharmacogenetic variants include:

- **rs11706052 (3757T>C)**: This promoter SNP disrupts a cAMP-responsive element, leading to reduced *IMPDH2* expression [3]. Patients carrying the C allele have lower IMPDH2 activity and may require lower doses of MPA to achieve the same immunosuppressive effect [4].
- **rs2288551 (c.788T>C, p.Leu263Phe)**: This non-synonymous variant is associated with diminished enzyme activity [3].
- **Other SNPs**: Numerous other SNPs in *IMPDH2* have been associated with the efficacy and toxicity of MPA, including neutropenia and acute rejection [1, 2, 3, 5, 6, 7, 8].

### 6.2 Investigational IMPDH2 Inhibitors

Beyond MPA, several other IMPDH inhibitors have been developed and evaluated in clinical trials:

- **AVN944 (also known as VX-944)**: This is an orally bioavailable, small-molecule inhibitor of both IMPDH1 and IMPDH2. It has been evaluated in Phase I clinical trials for the treatment of hematologic malignancies, including acute myeloid leukemia (AML) and multiple myeloma [4, 5]. AVN944 has also shown preclinical efficacy in Ewing's sarcoma [8].
- **Ribavirin**: This antiviral drug is a nucleoside analog that inhibits IMPDH, among other targets. It is used to treat HCV, RSV, and other viral infections.
- **Tiazofurin**: This C-nucleoside is metabolized to an NAD⁺ analog (TAD) that inhibits IMPDH. It has been investigated as an antineoplastic agent.
- **Mycophenolate analogs**: Several novel MPA analogs with improved pharmacokinetic properties are in development.

### 6.3 Drug Resistance and Combination Strategies

Resistance to IMPDH2 inhibitors can arise through several mechanisms, including:

- **Gene amplification**: Amplification of the *IMPDH2* gene locus leads to increased enzyme expression, which can overcome the inhibitory effect of the drug.
- **Point mutations**: Mutations in the drug-binding site can reduce the affinity of the inhibitor.
- **Upregulation of the salvage pathway**: Cells can increase the expression of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to salvage preformed guanine bases, bypassing the need for *de novo* synthesis.

To overcome resistance, combination strategies are being explored. For example, in pancreatic cancer, IMPDH2 inhibition has been shown to potentiate the effects of KRAS inhibitors [7]. In MLL-rearranged leukemias, guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition [6]. In glioblastoma, targeting IMPDH2 in combination with temozolomide may overcome chemoresistance [4, 5].

### 6.4 Gene Therapy and Cell Selection

The MPA-resistant form of IMPDH2 has been used as a selectable marker in gene therapy. By transducing cells with a vector encoding a mutant IMPDH2 that is resistant to MPA, it is possible to selectively expand the transduced cells in the presence of the drug. This approach has been explored for the ex vivo expansion of T cells and hematopoietic stem cells for HIV gene therapy [2, 3, 7].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for *IMPDH2*.

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| **NCBI Gene** | 3615 | https://www.ncbi.nlm.nih.gov/gene/3615 |
| **Ensembl** | ENSG00000178035 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178035 |
| **UniProt** | P12268 | https://www.uniprot.org/uniprotkb/P12268/entry |
| **RCSB PDB** | 1NF7 (and others) | https://www.rcsb.org/structure/1NF7 |
| **HGNC** | 6051 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6051 |
| **OMIM** | 146410 | https://www.omim.org/entry/146410 |
| **ClinVar** | Gene: IMPDH2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=IMPDH2%5Bgene%5D |
| **STRING** | P12268 | https://string-db.org/network/9606.ENSP00000310823 |
| **BioGRID** | 109332 | https://thebiogrid.org/109332 |
| **Gene Ontology (GO)** | GO:0003938 (IMPDH activity); GO:0006177 (GMP biosynthetic process); GO:0005829 (cytosol) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Pratama, D., Ikawati, Z., & Hermawan, A. (2025). Association of IMPDH1 and IMPDH2 gene polymorphisms with efficacy and toxicity of mycophenolic acid treatment in renal transplant patients: a narrative review. *Indonesian Journal of Pharmacology and Therapy*. https://www.semanticscholar.org/paper/b3ae7117b7736e8fd41c6d4ed910974b70e5d7e4

[2] Chen, P.-S., Wu, M.-C., Tai, C.-H., Chang, Y.-Y., Lan, M., Chen, Y.-F., Lin, H.-I., Lee, N.-C., & Lin, C.-H. (2023). Genetic analysis of IMPDH2 gene in Taiwanese patients with isolated or combined dystonia. *Parkinsonism & Related Disorders*. https://www.semanticscholar.org/paper/a5f73c0f1607c03a4862766b4497f805cf001187

[3] Glesne, D., Collart, F., Varkony, T., Drabkin, H., & Huberman, E. (1993). Chromosomal localization and structure of the human type II IMP dehydrogenase gene (IMPDH2). *Genomics*. https://www.semanticscholar.org/paper/66cd4e6599ba64ed794e3d517764e7b2b634f03b

[4] Wu, T.-Y., Peng, Y., Pelleymounter, L., Moon, I., Eckloff, B., Wieben, E., Yee, V., & Weinshilboum, R. (2010). Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. *British Journal of Pharmacology*. https://www.semanticscholar.org/paper/ab9585702452c1ed2f1e5014cc471fa0db31a715

[5] Garat, A., Lino Cardenas, C. L., Lionet, A., Devos, A., Glowacki, F., Kénani, A., Migot-Nabias, F., Allorge, D., Lo-Guidice, J., Broly, F., & Cauffiez, C. (2011). Inter-ethnic variability of three functional polymorphisms affecting the IMPDH2 gene. *Molecular Biology Reports*. https://www.semanticscholar.org/paper/ee55453b4394eaa06d5c4af1c89e038aa42bd51d

[6] Chew, A.-M., Choi, J. Y., Koshy, B., Lee, H. H., & Stephens, J. C. (2001). Haplotypes du gene impdh2. *Scientific Publication*. https://www.semanticscholar.org/paper/0841693b52a58cf23a5b9e34167d3c496cddd890

[7] Kuukasjärvi, A., Landoni, J., Kaukonen, J., Juhakoski, M., Auranen, M., Torkkeli, T., Velagapudi, V., & Suomalainen, A. (2021). IMPDH2: a new gene associated with dominant juvenile-onset dystonia-tremor disorder. *European Journal of Human Genetics*. https://www.semanticscholar.org/paper/048dcc133978c83957faa955cfaff10d0b30bf8d

[8] Wang, J., Zeevi, A., Webber, S., Selby, R., Sher, L., Fu, J., Phongsamran, P. V., McCurry, K., Hutchinson, I., & Burckart, G. (2006). NOVEL GENE POLYMORPHISMS IN THE IMPDH2 GENE